Theratechnologies announces availability of EGRIFTA WR

Theratechnologies (THTX) announced the availability of EGRIFTA WR for injection for the reduction of excess abdominal fat in adult patients with HIV and lipodystrophy. The announcement follows the approval of EGRIFTA WR by the U.S. Food and Drug Administration, FDA, earlier this year. The new formulation of tesamorelin for injection will gradually replace EGRIFTA SV, the current formulation. Specialty pharmacies are now ordering EGRIFTA WR to fill prescriptions for the new formulation. EGRIFTA SV will continue to be available during a transitional period as managed care plans increasingly provide coverage for EGRIFTA WR.